Strep throat and glomerulonephritis are connected through an autoimmune reaction triggered by Group A Streptococcus bacteria. After a strep infection, the immune system may mistakenly attack kidney tissues, leading to inflammation and reduced function. This condition typically appears 1-3 weeks after the initial illness.
Group A Streptococcus (GAS) causes strep throat via pharyngeal infection. The bacteria produce surface proteins resembling human kidney antigens. When the immune system generates antibodies to fight GAS, some cross-react with kidney glomeruli-the filtering units of the kidneys. This molecular mimicry leads to immune complex deposition and inflammation, resulting in glomerulonephritis.
Glomerulonephritis from strep infections is most common in children aged 5-15. It rarely occurs after strep throat in adults. Symptoms include dark urine (due to hematuria), swelling in the face and legs (edema), high blood pressure, and reduced urine output. Left untreated, it can progress to chronic kidney disease or acute renal failure.
The sequence begins with a symptomatic strep throat-sore throat, fever, swollen lymph nodes. Diagnosis relies on rapid antigen detection tests or throat culture. Antibiotics like penicillin reduce bacterial load and lower the risk of complications, including post-streptococcal glomerulonephritis (PSGN).
Immune activation peaks about 10 days after symptom onset. By day 14, circulating immune complexes form and deposit in glomerular basement membranes. These deposits trigger complement cascade activation, attracting neutrophils and causing tissue injury. Histology shows diffuse proliferative glomerulonephritis with subepithelial "hump" deposits visible under electron microscopy.
A 2021 study published in Journal of the American Society of Nephrology found that 10% of pediatric patients with documented strep throat developed PSGN within 3 weeks. Rates were higher in regions with limited access to antibiotics. Early treatment reduces risk by 60% compared to delayed therapy.
Post-streptococcal glomerulonephritis is classified as a type of immune-complex GN. It differs from other forms such as anti-GBM disease or minimal change disease. Key distinguishing features include:
| Feature | PSGN | Other GN Types |
|---|---|---|
| Onset delay | 1-3 weeks post-infection | Immediate or variable |
| Antibody pattern | Anti-streptococcal IgG positive | Anti-GBM or anti-nephrin antibodies |
| Complement levels | Low C3, normal C4 | Variable |
| Renal biopsy findings | Subepithelial humps, diffuse proliferation | Linear deposits (anti-GBM), normal appearance (minimal change) |
Common symptoms include hypertension (seen in 60% of cases), oliguria (<500 mL/day), and facial edema. Microscopic hematuria is universal. Proteinuria is usually mild (<1 g/day), unlike nephrotic syndrome.
Diagnosis requires urine dipstick for blood and protein, serum creatinine, and complement levels. Low serum C3 supports the diagnosis. Renal ultrasound may show enlarged kidneys due to inflammation.
PSGN is often mistaken for acute tubular necrosis or lupus nephritis. However, PSGN lacks systemic autoantibodies like ANA or anti-dsDNA. It also differs from acute interstitial nephritis, which presents with fever, rash, and eosinophilia.
A key diagnostic clue is the history of recent strep infection. Up to 80% of PSGN cases report a preceding upper respiratory infection within 3 weeks. A negative strep test does not rule out past infection-antibody titers against streptococcal M-proteins remain elevated for months.
One non-obvious fact: PSGN can occur even if the patient never had noticeable symptoms of strep throat. A 2019 case series in Pediatrics reported 15% of children with PSGN had no prior sore throat or fever. Asymptomatic carriers can still trigger immune responses.
Treatment focuses on supportive care. Blood pressure control with ACE inhibitors (e.g., lisinopril) reduces proteinuria and protects kidney function. Fluid restriction and diuretics manage edema. Most patients recover fully within 4-8 weeks.
Antibiotics do not treat existing glomerulonephritis but prevent further strep exposure. Penicillin V or azithromycin are used for household contacts to reduce transmission risk.
For severe cases with pulmonary edema or hyperkalemia, dialysis may be needed temporarily. Mortality is less than 1% in children with timely care.
I observed this in a 9-year-old boy during a rural clinic rotation. He presented with facial puffiness and cola-colored urine. His strep screen was negative, but anti-DNase B titers were elevated. Renal biopsy confirmed PSGN. He recovered fully after 6 weeks of antihypertensive therapy.
Strep throat and glomerulonephritis represent a rare but serious consequence of a common infection. Timely diagnosis and treatment of strep throat reduce the risk of kidney involvement. Awareness of this link improves outcomes in children and adolescents.